Emily Bodnar’s rating is based within the anticipation of important milestones for Agenus in the approaching calendar year, particularly the possible filing of the Biologics License Software (BLA) for their guide drug prospect, botensilimab (bot). Agenus has dosed around 900 patients with bot throughout various strong tumors, showing a determinat